Transthorcic EchocardiographyTICM-SCPNCT07063147
TTE Improves Clinical Management of Stable Chest Pain
An observational study of Transthorcic Echocardiography and Stable Angina Pectoris, run by Tianjin Chest Hospital at 1 site in China.
Trial summary
The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Transthorcic Echocardiography, Stable Angina Pectoris, Coronary Artery Disease
- What is being tested?
- TTE
- How many people
- 50,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2025to 31 Dec 2040
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who were referred for TTE for the assessment of SCP suspected of CAD.
Who may be able to join
- symptomatic patients with SCP suspected of obstructive CAD.
- referred for TTE for the assessment of SCP.
- ≥18 years of age.
- signed informed consent.
Who cannot join
- acute coronary syndromes
- previous CAD or coronary revascularization
- nonsinus rhythm
- cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Tianjin Chest Hospital
Tianjin
Jia Zhou, zhoujiawenzhang@126.com, zhoujiawenzhang@126.com
About this study
Official title: Improving the Clinical Management of Stable Chest Pain Based on Imaging: a Registry of Transthorcic Echocardiography
The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. This study will determine if TTE-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.
- Conditions
- Transthorcic Echocardiography, Stable Angina Pectoris, Coronary Artery Disease, Major Adverse Cardiac Events, Invasive Coronary Angiography
- Being tested
- TTE
- Medical subject headings
- Angina, Stable, Coronary Artery Disease, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TTEDiagnostic test
All patients underwent TTE according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
| Study group | Role | What they receive |
|---|---|---|
| TTE | Not described Receives: Diagnostic Test: TTE |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major adverse cardiovascular events
Measured: 10 years
Secondary outcomes (3)
Invasive coronary angiography
Invasive coronary angiography occurred at follow-up after TTE, attributed to TTE results or unplanned.
Measured: 10 years
Medication prescription
Change for medication prescription of antiplatelet agents, anti-ischemic drugs, lipid-lowering agents, angiotensin-converting enzyme inhibition and so on, attributed to TTE results or unplanned,
Measured: 10 years
Coronary revascularization
PTCA, PCI or CABG occurred at follow-up after TTE, attributed to TTE results or unplanned.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2025
- Study start1 Jan 2025
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Transthorcic EchocardiographyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Tianjin Chest Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhou Jia, Tianjin Chest Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07063147
- Sponsor's protocol ID
- 2025KY-019-01
- Acronym
- TICM-SCP
- Status last verified
- Jul 2025
- First submitted
- 3 Jul 2025
- Last updated
- 18 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving the Clinical Management of Stable Chest Pain Based on Imaging: a Registry of Transthorcic Echocardiography
- ClinicalTrials.gov ID
- NCT07063147
- Acronym / sponsor ID
- TICM-SCP / 2025KY-019-01
- Conditions
- Transthorcic Echocardiography, Stable Angina Pectoris, Coronary Artery Disease, Major Adverse Cardiac Events, Invasive Coronary Angiography
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50,000 participants (estimated)
- Lead sponsor
- Tianjin Chest HospitalUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2040 (estimated)
- First posted
- 14 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. This study will determine if TTE-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TTE | – | Diagnostic Test: TTE |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who were referred for TTE for the assessment of SCP suspected of CAD.
Key inclusion criteria (4 listed)
- symptomatic patients with SCP suspected of obstructive CAD.
- referred for TTE for the assessment of SCP.
- ≥18 years of age.
- signed informed consent.
Key exclusion criteria (4 listed)
- acute coronary syndromes
- previous CAD or coronary revascularization
- nonsinus rhythm
- cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TTEAll patients underwent TTE according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary. | Diagnostic test | TTE |
Primary outcome
Major adverse cardiovascular events
Time frame: 10 years
3 secondary outcomes
Invasive coronary angiography
Time frame: 10 years
Medication prescription
Time frame: 10 years
Coronary revascularization
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jul 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Transthorcic Echocardiography and Stable Angina Pectoris, run by Tianjin Chest Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jia Zhou (+8615522485560, zhoujiawenzhang@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major adverse cardiovascular events (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2025.